227 related articles for article (PubMed ID: 35147456)
1. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study.
Yao J; Liang X; Liu Y; Li S; Zheng M
Cancer Control; 2022; 29():10732748211051548. PubMed ID: 35147456
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
[TBL] [Abstract][Full Text] [Related]
3. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
[No Abstract] [Full Text] [Related]
4. Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends.
Wang J; Li E; Yang H; Wu J; Lu HC; Yi C; Lei J; Liao W; Wu L
World J Surg Oncol; 2019 Feb; 17(1):43. PubMed ID: 30813932
[TBL] [Abstract][Full Text] [Related]
5. Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States.
Mukkamalla SKR; Naseri HM; Kim BM; Katz SC; Armenio VA
J Natl Compr Canc Netw; 2018 Apr; 16(4):370-376. PubMed ID: 29632056
[No Abstract] [Full Text] [Related]
6. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States.
McGlynn KA; Tarone RE; El-Serag HB
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1198-203. PubMed ID: 16775181
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.
Welzel TM; Graubard BI; Zeuzem S; El-Serag HB; Davila JA; McGlynn KA
Hepatology; 2011 Aug; 54(2):463-71. PubMed ID: 21538440
[TBL] [Abstract][Full Text] [Related]
8. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor.
Garancini M; Goffredo P; Pagni F; Romano F; Roman S; Sosa JA; Giardini V
Liver Transpl; 2014 Aug; 20(8):952-9. PubMed ID: 24777610
[TBL] [Abstract][Full Text] [Related]
9. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States.
Lee YT; Wang JJ; Luu M; Noureddin M; Kosari K; Agopian VG; Rich NE; Lu SC; Tseng HR; Nissen NN; Singal AG; Yang JD
J Natl Cancer Inst; 2021 Nov; 113(11):1531-1541. PubMed ID: 34010422
[TBL] [Abstract][Full Text] [Related]
10. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.
Ding J; Wen Z
BMC Cancer; 2021 Oct; 21(1):1157. PubMed ID: 34715816
[TBL] [Abstract][Full Text] [Related]
11. Impact of liver fibrosis score on prognosis after common therapies for intrahepatic cholangiocarcinoma: a propensity score matching analysis.
Zhang JX; Li P; Chen Z; Lin H; Cai Z; Liao W; Pan Z
BMC Cancer; 2020 Jun; 20(1):556. PubMed ID: 32539768
[TBL] [Abstract][Full Text] [Related]
12. Combined Hepatocellular Cholangiocarcinoma: A Population-Based Retrospective Study.
Ramai D; Ofosu A; Lai JK; Reddy M; Adler DG
Am J Gastroenterol; 2019 Sep; 114(9):1496-1501. PubMed ID: 31335362
[TBL] [Abstract][Full Text] [Related]
13. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population-based analysis.
Spolverato G; Bagante F; Tsilimigras D; Ejaz A; Cloyd J; Pawlik TM
J Surg Oncol; 2019 Mar; 119(3):278-287. PubMed ID: 30554420
[TBL] [Abstract][Full Text] [Related]
14. Have incidence rates of liver cancer peaked in the United States?
Petrick JL; Florio AA; Loomba R; McGlynn KA
Cancer; 2020 Jul; 126(13):3151-3155. PubMed ID: 32294255
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma in a low-endemic area: rising incidence and improved survival.
Witjes CD; Karim-Kos HE; Visser O; van den Akker SA; de Vries E; Ijzermans JN; de Man RA; Coebergh JW; Verhoef C
Eur J Gastroenterol Hepatol; 2012 Apr; 24(4):450-7. PubMed ID: 22273986
[TBL] [Abstract][Full Text] [Related]
16. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
Zhou Q; Cai H; Xu MH; Ye Y; Li XL; Shi GM; Huang C; Zhu XD; Cai JB; Zhou J; Fan J; Ji Y; Sun HC; Shen YH
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):13-20. PubMed ID: 33160852
[TBL] [Abstract][Full Text] [Related]
17. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States.
Altekruse SF; Petrick JL; Rolin AI; Cuccinelli JE; Zou Z; Tatalovich Z; McGlynn KA
PLoS One; 2015; 10(3):e0120574. PubMed ID: 25837669
[TBL] [Abstract][Full Text] [Related]
18. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
[TBL] [Abstract][Full Text] [Related]
19. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.
Ha J; Yan M; Aguilar M; Bhuket T; Tana MM; Liu B; Gish RG; Wong RJ
Cancer; 2016 Aug; 122(16):2512-23. PubMed ID: 27195481
[TBL] [Abstract][Full Text] [Related]
20. Influence of postoperative adjuvant transarterial chemoembolization on the prognosis of early-stage intrahepatic cholangiocarcinoma: a single center study.
Liu G; Guo W; Wang H; Liu W; Lei L; Xie Q; Li X; Zou S; Wang P; Zhou H; Hu H
Ann Palliat Med; 2021 Apr; 10(4):3673-3683. PubMed ID: 33691434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
